Ceribell
Ceribell focuses on making electroencephalography accessible, efficient, and cost-effective.
About Ceribell
Ceribell focuses on making electroencephalography (EEG) widely accessible, more efficient, and more cost-effective. The company creates and validates an FDA cleared instant EEG system that does not require an EEG technologist or specialist interpreter, which allows for faster results and clinical decision-making. The Ceribell EEG System can be set up by any healthcare provider in 6 minutes and offers a proprietary Brain Stethoscope function that dramatically simplifies interpretation of EEG results by converting brainwaves to sound so seizures can be detected by listening. Earlier diagnosis and focused treatment for patients with seizures, including non-convulsive seizures that can only be diagnosed with EEG, can significantly lower mortality, secondary brain injury, length of stay, and risk of complications.
Company Facts
- Headquarters
- Mountain View
- Operating Status
- active
- Company Type
- for_profit
- IPO Status
- public
- Employees
- c_00251_00500
- Funding Stage
- ipo
- Total Funding
- $171,000,000
- Last Funding Type
- series_c
- Last Funding Date
- 2022-09-21
- Website
- ceribell.com
Industries & Categories
Biotechnology, Health Care, Health Diagnostics, Medical Device
Social Links
Canonical: https://fsome.com/organization/ceribell-2442 · For the full interactive profile (funding rounds, investors, team, portfolio, charts), please enable JavaScript.